DexCom (DXCM) is a publicly traded Connected Wearables company founded in 1999 and based in San Diego, United States.
United States| Date | Stage | Amount | Valuation | Lead investors |
|---|---|---|---|---|
| Apr 14, 2005 | IPO | $56.4M | — | Piper Jaffray |
| Jun 5, 2002 | Series C | $30M | — | RWI Group and Affiliates |
DexCom reported Q1 2026 revenue of $1.192 billion, up 15% year-over-year on a reported basis and 12% organically. GAAP operating income reached $255.3 million (21.4% margin), up 850 basis points from Q1 2025; GAAP net income was $199.5 million, or $0.51 per diluted share, versus $0.27 in the prior year. Gross margin improved to 62.9% from 56.9% year-over-year. The company expanded Dexcom G7 15-Day CGM distribution across all U.S. channels and introduced enhanced Smart Meal Logging features for its Stelo platform. For full-year 2026, DexCom raised guidance on non-GAAP operating margin and adjusted EBITDA margin while reiterating revenue guidance of $5.16–$5.25 billion (11–13% growth) and non-GAAP gross margin of 63–64%.
FY2026 revenue $5.16–$5.25B (11–13% growth); non-GAAP gross margin ~63–64%; non-GAAP operating margin ~23–23.5%; adjusted EBITDA margin ~31–31.5%
Co-founded DexCom in 1999 alongside Scott Glenn, John Burd, Lauren Otsuki, and Ellen Preston, building the company that would pioneer continuous glucose monitoring. Prior to DexCom, Megargel earned an MBA from Stanford University (1998) and focused on healthcare venture capital. He was also a co-founder of Avera Pharmaceuticals and held roles at Planet Biopharmaceuticals (Vice President), Windamere Venture Partners, and Mdedge. Megargel passed away in 2021 at age 52.
One of five co-founders of DexCom in 1999 alongside Scott Glenn, John Burd, Lauren Otsuki, and Bret Megargel. Prior to co-founding the continuous glucose monitor company, Preston built a career in medical device and healthcare sales and marketing spanning roughly 30 years, including roles at Johnson & Johnson — where she helped create a new product category and reshape pricing and delivery of contact lenses — and the Arizona Health Sciences Center (AHSC). She studied at Arizona State University. Her background in commercializing paradigm-changing medical products provided the commercial and market-facing expertise that complemented the scientific founders on the early DexCom team.
A biochemist by training (BS, Purdue; MS and PhD, University of...), Burd began his career at Miles Laboratories (Ames) in 1977, developing fluorescent immunoassays for diabetes diagnostics. That work laid the technical foundation for his co-founding DexCom in 1999, where as President and CEO he oversaw development of the first long-term implantable continuous glucose monitor. He holds roughly 35 patents and has authored 40+ publications. Post-DexCom, Burd founded Lysulin (2017), a nutritional supplement company targeting blood sugar management — extending his focus on diabetes beyond sensing into metabolic intervention.
Co-founded DexCom in 1999 alongside Scott Glenn, John Burd, Ellen Preston, and Bret Megargel, serving as a Vice President during the company's early years. Prior to DexCom, Otsuki founded a string of life-sciences ventures including SkinMedica (a clinical skincare company later acquired by Allergan) and Alastin Skincare. She also co-founded Prometheus Biosciences (now Prometheus Biosciences Inc.), NovaCardia, and Oncternal Therapeutics — collectively spanning dermatology, cardiovascular, oncology, and diagnostics. She holds a B.S. from the University of California, Davis. Across two decades, she has founded or co-founded five biotech firms, several of which reached public-market or acquisition exits.
Prior to co-founding DexCom in 1999, Glenn had already founded Prometheus Laboratories (1995) and Santarus (1996), and had been managing partner at Windamere Venture Partners since 1994 — a firm through which he pioneered a venture-company creation model that ultimately produced over two dozen life sciences startups. Earlier ventures included SkinMedica (acquired by Allergan) and, later, Zogenix, Somaxon Pharmaceuticals, and Evoke Pharma. He holds a B.S. from California State University and, after a five-year tenure as DexCom's chairman and founder, stepped away in 2004, well before the G4, G6, and G7 sensors made the company a CGM market leader.
Dexcom's Stelo OTC glucose sensor gains FDA clearance for children as young as two years old.
DexCom, Abbott, and Insulet showcase upcoming diabetes management technologies at the ADA Scientific Sessions.
Dexcom releases study data supporting glucose-sensor use for non-insulin-dependent Type 2 diabetes patients.
Dexcom G7 is the company's latest continuous glucose monitoring (CGM) system, featuring a fully integrated all-in-one sensor and transmitter worn on the upper arm. It delivers real-time glucose readings directly to a smartphone with a 30-minute warm-up — the shortest of any CGM on the market. The G7 supports 10-day wear (with a 15-day version available), is compatible with automated insulin delivery (AID) systems like Omnipod 5 and Tandem t:slim X2, and enables direct-to-Apple-Watch connectivity so users can view glucose data without carrying their phone. Its smaller, streamlined design and improved accuracy at the low end make it a top choice for people with Type 1 and Type 2 diabetes managing intensive insulin therapy.
Dexcom G6 is the previous-generation CGM system that set the standard for fingerstick-free diabetes management. It uses a two-piece design — a disposable sensor worn for 10 days and a reusable transmitter that lasts up to three months — to stream real-time glucose data to a smartphone or compatible receiver. The G6 requires no routine fingerstick calibration and offers customizable alerts for high and low glucose levels. It leads the industry in pump connectivity, integrating with multiple automated insulin delivery systems including Tandem, Omnipod, and Insulet devices, making it a reliable choice for users who need robust interoperability.
Stelo is Dexcom's over-the-counter (OTC) CGM launched in 2024, available without a prescription for adults with Type 2 diabetes who do not use insulin. It provides continuous glucose readings and insights directly to a smartphone app, helping users understand how food, activity, and daily routines affect their blood sugar. Stelo is designed for the broader wellness and prediabetes market — people who want to track their glucose patterns to make informed lifestyle adjustments. It uses the same sensor technology as Dexcom's prescription CGMs but is tailored with a simplified app experience focused on education and trend awareness rather than clinical alerts.
We don't have a live feed for this company's ATS. Their careers page has every open role.
View all careers ↗
